Vedolizumab for the treatment of ulcerative colitis

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

(2016) Gaik W. Tew et al.   GASTROENTEROLOGY

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis

(2015) Francesco Ciccia et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis

(2015) Matilda Hagan et al.   Expert Opinion On Drug Safety

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

(2015) Brian Bressler et al.   GASTROENTEROLOGY

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?

(2015) A. Stallmach et al.   Journal of Crohns & Colitis

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

(2015) Parambir S. Dulai et al.   PHARMACOTHERAPY

Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?

(2015) Javier P. Gisbert et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis

(2015) Yu Jin   WORLD JOURNAL OF GASTROENTEROLOGY

Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung

(2015) S. Schreiber et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

a4�7 Integrin (LPAM-1) is Upregulated at Atherosclerotic Lesions and is Involved in Atherosclerosis Progression

(2014) Kangkang Zhi et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

(2014) Mahmoud H. Mosli et al.   DRUGS

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

An Update on Anti-TNF Agents in Ulcerative Colitis

(2014) Mark A. Samaan et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

(2014) Tim Wyant et al.   GUT

A Nationwide 2010–2012 Analysis of U.S. Health Care Utilization in Inflammatory Bowel Diseases

(2014) Welmoed K. van Deen et al.   INFLAMMATORY BOWEL DISEASES

Long-term Prognosis of Ulcerative Colitis and its Temporal Change Between 1977 and 2013: A Hospital-based Cohort Study from Korea

(2014) Ho-Su Lee et al.   Journal of Crohns & Colitis

Immunosuppressive therapies for inflammatory bowel disease

(2014) Talia Zenlea   WORLD JOURNAL OF GASTROENTEROLOGY

Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

(2014) Tim Raine   United European Gastroenterology Journal

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors

(2013) A. C. Moss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Moving towards disease modification in inflammatory bowel disease therapy

(2013) Patrick B. Allen et al.   CURRENT OPINION IN GASTROENTEROLOGY

Mucosal Addressin Cell Adhesion Molecule (MAdCAM-1) Expression Is Upregulated in the Cirrhotic Liver and Immunolocalises to the Peribiliary Plexus and Lymphoid Aggregates

(2013) Aftab Ala et al.   DIGESTIVE DISEASES AND SCIENCES

Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease

(2013) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Antagonizing the  4 1 Integrin, but Not  4 7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis

(2013) K. G. Haanstra et al.   JOURNAL OF IMMUNOLOGY

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

(2013) Catherine Milch et al.   JOURNAL OF NEUROIMMUNOLOGY

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

(2013) Tim Wyant et al.   mAbs

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

(2012) Eric R. Fedyk et al.   INFLAMMATORY BOWEL DISEASES

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

(2012) David Laharie et al.   LANCET

Epidemiology and Natural History of Inflammatory Bowel Diseases

(2011) Jacques Cosnes et al.   GASTROENTEROLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz

(2011) A. Dignass et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Adverse effects of biologics used for treating IBD

(2010) Andreas Stallmach et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)

(2008) Inger Camilla Solberg et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY